U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971731) titled 'A Phase 3 Study of JNT-517 in Participants With Phenylketonuria' on May 07.
Brief Summary: The goal of this Phase 3, randomized study is to assess the safety, efficacy, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adults (18 years of age or older) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 2 in 3 (or approximately 67%) chance of receiving JNT-517 during the first part of the study which will last approximately six weeks. During the second part of the study every participant who continues in the study will receive one of two do...